Navigation Links
General Anesthesia For Heroin Detoxification Is No Good

Research studies have shown that use of general anesthesia for heroin detoxification is no better when compared to other methods of detoxification. The study, which came in the latest issue of JAMA, also points out the fact that use // of general anesthesia in these circumstances can also lead to adverse life threatening events.

Medically supervised heroin withdrawal remains plagued by patient discomfort and high dropout rates. Many patients fear the physical discomfort of withdrawal and either avoid treatment or leave it prematurely. Even those who complete the detoxification process have high relapse rates, partly due to the absence of continuing treatment.

These problems have given rise, in the past 15 years, to ultra-rapid, or anesthesia-assisted opioid detoxification, which involves administering an opioid antagonist drug to neutralize the effects of heroin while the patient is unconscious from general anesthesia.

This has been publicized as a fast, painless way to withdraw from heroin. However, this treatment is expensive, not covered by insurance, and lacks good evidence to support efficacy. There are also significant concerns about health risks. The detoxification procedure is usually followed by longer-term treatment with an antagonist drug such as naltrexone to block the effects of any subsequent heroin use.

Researchers from Columbia University, New York, had conducted a randomized controlled trial between 2000 and 2003 to evaluate the safety, tolerability, and efficacy of anesthesia-assisted rapid opioid detoxification compared with two other inpatient withdrawal and naltrexone treatment procedures.

The researchers found that average withdrawal severities were comparable across the 3 treatments. Treatment retention over 12 weeks was low and not significantly different among the three groups. Overall, only 11 percent of patients continued in treatment for 12 weeks and had less than two opioid-posit ive urine tests, indicating a high rate of relapse to heroin use. The anesthesia procedure was associated with 3 potentially life-threatening adverse events: severe pulmonary edema and aspiration pneumonia, diabetic ketoacidosis, and a bipolar mixed state requiring hospitalization.

Researchers feel that the study demonstrates no benefit of anesthesia over a safer, cheaper, and potentially outpatient alternative using buprenorphine as a bridge to naltrexone treatment. Taken together with the results of earlier studies, the findings suggest that general anesthesia for rapid antagonist induction does not currently have a meaningful role to play in the treatment of opioid dependence

Source: Newswise

Related medicine news :

1. Bypass Heart Surgery Performed Without General Anesthesia
2. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
3. General Practitioners are earning mighty amount?
4. Former IMO President Shows Interest In Winning General Election
5. Severe Paucity of General Practitioners in Australia
6. WHO Director-General passes away on 23rd of May
7. Drug Controller General to Withdraw Drug that Affects Vulture Population
8. IT for General Practitioners
9. Fewer Graduates Choosing General Practice
10. Stroke Rehab Programs Should Be Generalized
11. China Nominates Margaret Chan to Run for WHO Director-Generals Post
Post Your Comments:

(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three ... learned from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. The purchase ... technical experience available within DataTrade to extend the services currently provided by Healthjump. ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... ), a leading provider of enterprise Time and Attendance/Workforce Management cloud-based ... in the Microsoft Partner Program with competencies in the Application Development, demonstrating ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... 2016. In 2016, expected coding changes are likely to include new codes for ... It’s not easy to understand the effects of code changes in musculoskeletal, radiology ...
(Date:11/29/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute ... peer review process that allows practices to demonstrate that they meet or ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... new medicines directed at up to 10 G protein-coupled ... PFE ) to research and develop potential new ... (GPCR) targets across multiple therapeutic areas. --> ... and development company and wholly-owned subsidiary of Sosei Group ...
(Date:11/30/2015)... , November 30, 2015 ... or the "Company") announced today that it was informed by ... and Drug Safety (MFDS) has approved its Exablate Neuro ... --> --> Insightec,s Exablate ... treatment alternative that combines two technologies: Focused Ultrasound, which ...
Breaking Medicine Technology: